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Quantum dot encapsulation in virus-like particles
with tuneable structural properties and low
toxicity†
O. Tagit, ‡* M. V. de Ruiter, M. Brasch, Y. Ma and J. J. L. M. Cornelissen *
A simple method for the encapsulation of quantum dots (QDs) in virus-like particle (VLP) nanoassemblies
with tuneable structural properties and enhanced biocompatibility is presented. Cowpea chlorotic mottle
virus-based capsid proteins assemble around the carboxylated QDs to form QD/VLP nanoassemblies of
diﬀerent capsid size as a function of pH and ionic strength. Detailed structural characterizations verify
that nanoassemblies with probably native capsid icosahedral symmetry (T ¼ 3) are obtained at low pH
and high ionic strength (pH 5.0, 1.0 M NaCl), whereas high pH and low ionic strength conditions (pH 7.5,
0.3 M NaCl) result in the formation of smaller assembly sizes similar to T ¼ 1 symmetry. In vitro studies
reveal that QD/VLP nanoassemblies are eﬃciently internalized by RAW 264.7 macrophages and HeLa
cells with no signs of toxicity at QD concentrations exceeding the potentially-toxic levels. The presented
route holds great promise for preparation of size-tuneable, robust, non-toxic luminescent probes for
long term cellular imaging applications. Furthermore, thanks to the possibility of chemical and genetic
manipulation of the viral protein shell encaging the QDs, the nanoassemblies have potential for in vivo
targeting applications.
Introduction
Luminescent nanostructures engineered at the nanoscale are
promising candidates to satisfy requirements of a variety of
biological applications such as in vitro imaging and therapeutic
interventions.1,2 Semiconductor quantum dots (QDs) are an
attractive class of materials for such applications due to their
unique size-tuneable optical properties, size in the nanometer
range and resistance to photobleaching.3 However, their
potential cytotoxicity is an ongoing concern particularly for
long-term, in vivo exposures or live cell imaging and needs to be
addressed before the realization of in vitro and in vivo applica-
tions.4 The strong dependence of QD toxicity to concentration,
size, charge, and stability of surface ligands5,6 has increased the
need for biocompatible and robust scaﬀolds to encage QDs.
Virus-like particles (VLPs) constitute an example of natural
protein cages that oﬀer great potential as robust and mono-
disperse hollow scaﬀolds with a highly organized supramolec-
ular structure.7–9 In this respect, there has been a growing
interest in using these biomolecular architectures as nano-
templates and nanoreactors for modulating the assembly10,11
and growth12 of nanoparticles due to the natural ability of bio-
logical structures to organize on many length scales with
controlled size, shape, alignment and orientation. Moreover,
viral particles are amenable to both chemical modications and
genetic manipulations and are designed by nature to stabilize
and shield their cargo from their surroundings. Therefore,
encapsulation of QDs within such well-dened biomolecular
structures would not only prevent the potential QD toxicity but
also enable e.g. in vivo targeting via capsid protein
modications.
A number of studies have explored the formation of VLP/
inorganic nanoparticle assemblies via either assembly of the
cage proteins around the inorganic cores,7,10,11,13–16 or in situ
formation of inorganic nanoparticles within the assembled
capsids.12,17,18 In the former case, the guest molecules are
entrapped within the cage during capsid assembly via comple-
mentary electrostatic interactions, whereas in the latter, the
precursor molecules diﬀuse into the pre-formed cage to form
nanocrystals. VLP self-assembly around inorganic ‘guests’ has
been explored for gold nanoparticles,7,19–22 magnetic cores,23–26
and QDs10,14,16,27–29 among others, which have been discussed in
recent reviews.30–32 In this work, we extend the QD encapsula-
tion concept to cowpea chlorotic mottle virus (CCMV)-based
protein cages. CCMV is a member of the Bromoviridae family
of plant viruses with an icosahedral protein shell of 28 nm of
outer diameter and 18 nm of inner cavity.9 One of the highly
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interesting properties of CCMV is that the protein shell, which is
composed of 180 identical subunits, can reversibly disassemble
into 90 capsid protein (CP) dimers in vitro. Depending on the pH
and ionic strength, the reassembly process may result in capsids
of the same size and geometry as the wild type CCMV, or diﬀerent
capsids morphologies.33–35 In this respect, compared to other
virus-based protein cages, CCMV oﬀers the versatility to achieve
nanoassemblies of diﬀerent sizes and structural parameters. In
addition, its highly symmetrical structure enables multivalent
presentation of molecules (e.g. for targeting) conjugated to outer
surface while its inner cavity can host diﬀerent types of cargo.36
Furthermore, unlike adenoviruses, CCMV and other plant-
derived viruses are non-pathogenic for humans and are regar-
ded as safe for potential human use37 and have a broad in vivo
biodistribution without any toxicity.38 Therefore, CCMV-based
protein cages hold a great promise as biocompatible nano-
scaﬀolds for applications in nanomedicine such as targeted
drug delivery systems. Alternatively, when combined with
contrast agents such as QDs, they can serve as powerful tools as
non-toxic probes for long-term, disease-specic imaging.39 In this
work, we explore the encapsulation of QDs within CCMV-based
protein cages and demonstrate their biocompatibility and in
vitro imaging applications. Depending on the pH and ionic
strength, CCMV-based CPs assembled around the carboxylic
acid-functionalized QDs to form hybrid particles of two diﬀerent
sizes (Fig. 1). Detailed colloidal and optical characterization of
these nanoassemblies as size-tuneable, non-toxic, luminescent
imaging probes is discussed.
Experimental
Materials
Qdot® 605 ITK™ carboxylated CdSe/ZnS core/shell QDs (peak
emission at 605 nm) were purchased from ThermoFisher
Scientic. Isolation and purication of CCMV, removal of viral
RNA and isolation of CPs was performed as reported
previously.12,33
Encapsulation
20 mL of 8 mM carboxylated QDs were mixed with 50 mL of dis-
assembled CCMV CP solution (8.8 mg mL1). The protein-QD
mixture was dialyzed against either sodium acetate buﬀer
(50 mM, 1.0 M NaCl, 1.0 mM NaN3, pH 5.0) or Tris–HCl buﬀer
(50 mM, 0.3 M NaCl, 1.0 mM DTT, pH 7.5) for 2 days.
Characterization
Fast protein liquid chromatography (FPLC), which enabled both
purication and structural characterization of nanoassemblies,
was performed using a Superose 6 column (GE Healthcare). All
the buﬀers used for FPLC were ltered using a Millipore lter
(0.2 mm pore size) before use. Protein concentration was
determined using a NanoDrop 1000 spectrometer (Thermo
Scientic). The QD concentration encapsulated within the virus
capsids was determined with a Perkin Elmer Lambda 850 UV/vis
spectrometer. Emission spectra of the QDs were recorded with
a Perkin Elmer LS55 uorescence spectrometer.
The size distribution of the VLPs was measured using
dynamic light scattering (DLS) with a Microtrac Nanotrac Wave
W3043. Viscosity and refractive index of the buﬀer were
assumed to be identical to water. For the refractive index of
particles, that of native CCMV (1.54) was used. Furthermore, the
VLPs were imaged with transmission electron microscopy
(TEM) on a FEG-TEM (Phillips CM 30) operated at 300 kV
acceleration voltages. Samples were prepared on formvar
Carbon 200 copper grids by incubating the samples for 1 min,
draining the liquid, followed by 1% uranyl acetate staining for
15 seconds. The diameter of imaged particles was measured
Fig. 1 Schematic presentation of the expected generation of quantum dot (QD)/virus-like particle (VLP) hybrid nanoassemblies. (I) At high pH
(7.5) and high ionic strength (1.0 M NaCl) cowpea chlorotic mottle virus (CCMV) disassembles into capsid protein dimers (CP dimers) and RNA is
removed. Re-assembly is carried out in the presence of carboxylic acid-functionalized QDs. (II) QD/VLP assemblies with T ¼ 1 symmetry are
formed at high pH (7.5) and low ionic strength (0.3 M NaCl). (III) Low pH (5.0) and high ionic strength (1.0 M NaCl) conditions result in the
formation of QD/VLP assemblies with T ¼ 3 symmetry.






























































































with ImageJ to determine the size distribution. Particles were
measured in two orthogonal directions.
In vitro imaging of RAW 264.7 macrophages
Approximately 1014 QD-loaded VLPs in their corresponding
buﬀer, without the NaN3 and DTT, were mixed with 10
3 to 104
seeded RAW 264.7 macrophages in 100 mL growth medium and
were incubated overnight (more than 18 h) at 37 C. Aerwards
cells were washed three times with fresh medium to remove the
excess of material. Confocal laser scanning microscopy (CLSM)
images of the cells were obtained using a Zeiss LSM 510 (Carl
Zeiss Microimaging GmbH, Go¨ttingen, Germany) confocal
scanning system with a 20 objective. An Ar-ion laser (458 nm)
was chosen as the excitation light source and emission was
collected using a LP 560 lter for QD imaging. Images were
processed with ImageJ. Cells incubated only with QDs (50 nM)
were also imaged as control. Intracellular uorescence inten-
sities were determined by ImageJ using at least 65 individual
cells. Statistical analysis was performed using GraphPad Prism
soware.
MTT assay
RAW cells seeded on a 96 well-plate (5  103 cells per well) were
incubated with QDs and nanoassemblies in equal QD concen-
trations for 4 h. Cells were incubated for another 4 hours aer
addition of 20 mL of 5 mg mL1 MTT solution (freshly prepared
in PBS) in each well. At the end of the incubation period 150 mL
of DMSO was added to each well. Aer shaking the plate for
5 min absorbance of each well was measured at 490 nm using
a plate reader.
In vitro imaging of HeLa cells
50 nM QD/VLP nanoassemblies were mixed with5 103 HeLa
cells in 100 mL growth medium and were incubated overnight at
37 C. At the end of incubation period cells were washed three
times with fresh medium to remove the excess of material.
CLSM images were acquired using an Olympus FV1000
(Olympus, Tokyo, Japan) with a 60  1.35 NA Oil immersion
objective. Images were processed with ImageJ. Cells incubated
only with QDs (50 nM) were also imaged as control.
Results and discussion
The QD/VLP nanoassemblies were formed via two diﬀerent
routes. In both cases, wild-type CPs without any further modi-
cations, and commercially available QDs of the same size
(lemission 605 nm, 6.4 nm core diameter, Fig. ESI 1†) and
surface functionality (carboxylic acid) were used. In the rst
method the assembly was carried out at pH 5.0 in sodium
acetate buﬀer (1.0 M NaCl), whereas the second method
involved the use of Tris–HCl buﬀer (0.3 M NaCl) at pH 7.5 for
the capsid assembly. The experimental route is presented in
Fig. 1.
Purication and structural characterization of the QD/VLP
nanostructures was achieved by fast protein liquid chromatog-
raphy (FPLC). The elution of QDs and capsid proteins were
monitored at l ¼ 335 nm and 280 nm, respectively and the
corresponding fractions, where both peaks co-elute, were used
for further characterization. The elution prole of the assem-
blies prepared at pH 5.0 and pH 7.5 are shown in Fig. 2.
Assembly at pH 5.0 (1.0 M NaCl) resulted in two main structures
with elution volumes of 1.3 mL and 1.9 mL (Fig. 2a). When
compared to the FPLC chromatogram of native CCMV capsid
(Fig. ESI 2†), it can be concluded that the peaks observed at
1.3 mL and 1.9 mL correspond to assembled capsids and CP
dimers, respectively. The co-elution of QDs (335 nm) and CPs
(280 nm) at the same volume as the native capsid (1.3 mL)
suggests that encapsulation at pH 5.0 resulted in QD/VLP
structures similar to T ¼ 3 native capsid symmetry.
The elution prole of the nanohybrid structures assembled
at pH 7.5 (0.3 MNaCl) showed an intense peak around 2.4 mL in
addition to two overlapping peaks at 1.7 mL and 2.1 mL
(Fig. 2b). This intense peak likely originates from unencapsu-
lated QDs. The retarded elution of the QD/VLP hybrids implied
the formation of particles with sizes smaller than the wild type
CCMV capsid. Previous studies also demonstrated the assembly
of CPs into smaller size capsids to form T ¼ 1 particles, which
are 18 nm in diameter and consist of 30 CP dimers, or pseudo
T ¼ 2 particles of 22 nm size with 60 CP dimers in the presence
of negatively charged molecular species.35,40,41 The role of elec-
trostatic interactions between the positively-charged N-termini
of capsid proteins and the negatively-charged encapsulant in
the capsid assembly process has been investigated further by
other recent studies. For instance, Garmann et al. have reported
the preparation of CP mutants with extra and missing (relative
to the wild type CPs) N-terminal cationic residues that were
used for packaging of RNA. It was shown that a smaller and
larger excess of CPs was needed for complete packaging of RNA
by CP mutants bearing extra and missing cationic residues,
respectively.42 Another study investigating the assembly of CP
dimers around a single stranded RNA has reported the inu-
ence of ionic strength and pH on the assembly process in
details.43 Accordingly, the entire assembly process indeed
depends delicately on the strength of CP–CP attractions relative
to CP–cargo attractions. While CP–CP attractions are controlled
by pH, CP–cargo attractions are more sensitive to ionic strength.
CP–CP and CP–cargo attractive interactions decrease at high pH
and high ionic strength, respectively.44 Therefore, it can be
stated that CP–QD interactions of electrostatic nature mainly
drive the formation of QD/VLP nanohybrid structures at high
pH and low ionic strength (pH 7.5, 0.3 M NaCl). The Zeta
potential measurements (Table ESI 1†) performed in parallel to
size exclusion chromatography revealed that CPs that did not
form assembled capsids in the absence of carboxylated QDs had
a slightly positive charge probably due to exposed cationic N-
termini at pH 7.5 (0.3 M NaCl) (Fig. ESI 3a†). In the presence
of QDs, however, the assembly formation was veried by size
exclusion chromatography (Fig. ESI 3b†) and a net negative
charge was observed for the QD/VLP assemblies, which is in
accordance with the Zeta potential of the assembled capsids
(Table ESI 1†). Therefore, the peaks observed at 1.7 mL and 2.1
mL (Fig. 2b) can be assigned to T ¼ 1 particles and CP dimers
that failed to assemble into capsids, respectively. The inability






























































































of CP dimers to assemble around QDs implies the lack of charge
matching between CP N-terminus and negatively-charged QD
surface. Extended incubation of CP dimers at pH 7.5 was re-
ported to cause near-complete truncation of positively charged
amino acid residues on the CP N-terminus.45 A small degree
of the capsid proteins lost their N-terminal part at pH 7.5
(Fig. ESI 4†), lowering the formation of electrostatic attractive
forces between QDs and CPs. The formation of T ¼ 1 VLPs for
CCMV CPs was previously observed for serval other negatively
charged cargo systems as well.8,46,47 The encapsulation eﬃciency
was estimated as70% by calculating the ratio of the integrated
intensity of the QD elution curve at T¼ 1 peak over the total QD
elution curve. It is noteworthy that QDs have very high molar
extinction coeﬃcients and absorb strongly in the UV range
(Fig. ESI 1†). Therefore, QD absorption contributes to the
intensity levels monitored at 260 nm and 280 nm as well.
Formation of QD/VLP nanoparticles was mainly driven by
CP–CP interactions at low pH and high ionic strength (pH 5.0,
1.0 M NaCl). Negligible-ionization of carboxylic acid groups on
the QD surface at low pH probably equally contributed to the
formation of particles with T ¼ 3 native capsid symmetry
bearing packed QD cores with high encapsulation eﬃciency
(90%).
For further characterization, only the fractions containing
T ¼ 3 and T ¼ 1 particles were used. Fluorescent characteriza-
tion of the assemblies revealed that QD emission peak slightly
red-shied upon encapsulation (Fig. ESI 5†). This is a general
observation for the encaged QDs48,49 and implies QD encapsu-
lation within the protein cages. Furthermore, when compared
to absorption spectra of QDs, QD/VLP assemblies showed an
extra absorption shoulder at 280 nm that corresponded to
protein absorption (Fig. ESI 6†).
Dynamic light scattering (DLS) and transmission electron
microscopy (TEM) imaging experiments further veried QD
encapsulation within protein cages and formation of QD/VLP
nanoassemblies of diﬀerent sizes (Fig. 3). Five separate DLS
measurement were averaged to determine the particle size as
26.7 nm for the larger particles (Fig. 3a), 18.3 nm for the smaller
particles (Fig. 3b), and 27.3 nm for wild-type CCMV (Fig. ESI 7†).
Indeed, the obtained values corresponded very well to the re-
ported sizes of native CCMV T ¼ 3 and T ¼ 1 particles. Gel
electrophoresis also conrmed the presence of proteins in the
QD/VLP assemblies (Fig. ESI 4†). TEM imaging enabled visual
assessment of individual particles in terms of both size and QD
content. As depicted in Fig. 3c, a considerable number of QD/
VLP assemblies with presumed T ¼ 3 symmetry contain more
than one encapsulated QD, whereas ‘T ¼ 1 particles’ are
encapsulating single QDs per assembly (Fig. 3d). The average
number of QDs was estimated as 3 per VLP for nanoassemblies
with T ¼ 3 symmetry and 1.5 per VLP for those with T ¼ 1
symmetry based on the corresponding absorption spectra
(detailed calculations are shown in ESI). This observation also
supports the higher encapsulation eﬃciency for T ¼ 3 particles
as determined using FPLC.
In vitro imaging applications
The potential QD toxicity has raised considerable concerns for
their applications in biological environments requiring long
term exposure or live cell imaging. While in vitro toxicity of QDs
is usually associated with the release of heavy metal ions or
generation of reactive oxygen species, in vivo toxicity may exert
itself at the systemic level due to interactions with blood
components, accumulation in non-desired organs or generation
of immune responses.50 Because macrophage cells serve as the
rst line of immune defense against exogenous substances, it is
important to investigate the potential toxicity of nano-
assemblies using particularly this cell line. For this purpose, we
incubated RAW 264.7 macrophages with ‘T ¼ 1 and T ¼ 3’
particles for a period of more than 18 hours. Confocal laser
scanning microscopy imaging of the cells revealed a strong
emission originating only from the cell interior, localized in the
cytosol, for QD/VLP particles of both sizes (Fig. 4). The nuclear
compartments can be distinguished as the dark areas within
the cells (images with nuclear staining are shown in Fig. ESI 8†).
During the incubation period of more than 18 hours, the cells
Fig. 2 FPLC chromatograms of QD/VLP assemblies obtained at (a) pH 5.0; 1.0 M NaCl and (b) pH 7.5; 0.3 M NaCl. The elution of protein andQDs
were followed at 280 nm (blue) and 335 nm (black), respectively. Red curve corresponds to elution proﬁle at 260 nm.






























































































were observed to be viable as depicted by their stretched
conformation on the bottom of the wells. Parallel morpholog-
ical investigations of cells that were incubated with only QDs
(Fig. 4 and ESI 9†) of similar concentrations revealed reduced
cell viability and certain related morphological changes such as
granulation and apoptotic body formation.51
A recent study that has shown a detailed investigation of the
immune response of RAW 264.7 macrophages incubated with
commercially-available carboxylated CdSe/ZnS QDs also re-
ported a reduced cell viability within the rst 24 hours of
incubation,52 which supports our observations of reduced cell
viability in control experiments (Fig. ESI 10†). The viability of
cells incubated with the presumed T ¼ 1 and T ¼ 3 particles for
incubation times of 18 hours clearly show that QD cores were
well protected by VLPs against intracellular oxidation during
the incubation period and observations are consistent for both
particles.
Cellular uptake eﬃciency of nanoparticles depends largely
on the nanoparticle surface chemistries52,53 as well as the type
and origin of the cells.54,55 In order to study whether VLP
encapsulation interfered with the cellular uptake eﬃciency, we
compared the intracellular uorescence intensity levels of RAW
cells incubated with T ¼ 1 and T ¼ 3 assemblies as well as with
‘bare’ QDs (Fig. 5). Analysis of at least 65 individual cells for
each condition revealed similar intracellular uorescence
intensity levels for QD and T1 samples (P > 0.05), however both
of them had uorescence intensity signicantly higher than
that of T3 samples (P < 0.05). This observation was veried by
ow cytometry analysis as well (Fig. ESI 11†).
It should be noted that the photoluminescence quantum
yield (QY) of QD/VLP assemblies with T¼ 3 symmetry was found
to be smaller (0.75) compared to T ¼ 1 assemblies and QDs
(regarded as reference with QY ¼ 1). Therefore, the smaller
degree of intracellular uorescence intensity observed for T3
particles would not necessarily mean less particle uptake, but it
could be due to lower quantum yield of these assemblies.
Cell viability studies performed on RAW macrophages sug-
gested that QD/VLP nanoassemblies would be suitable for in
vitro and in vivo applications. The possibility to chemically and
genetically modify the VLPs would extend the potential appli-
cations of QD/VLP assemblies to targeted, disease-specic
imaging. We used human cervical cancer cell line (HeLa cells)
Fig. 3 Representative size distribution histograms of T¼ 3 (a) and T¼ 1 (b) particles obtained by dynamic light scattering. Values indicated on the
graphs are obtained by averaging over ﬁvemeasurements. Transmission electronmicroscopy images of T¼ 3 (c) and T¼ 1 (d) particles. Scale bar:
20 nm.






























































































to test the feasibility of potential tumor imaging applications
(Fig. 6). HeLa cells incubated with QDs and QD/VLP assemblies
with T ¼ 1 and T ¼ 3 symmetry revealed cellular uptake for all
samples. Similar to RAW macrophages, the uorescence signal
that accumulated in the perinuclear region (Fig. ESI 12†) was
less for T ¼ 3 assemblies compared to QDs and T ¼ 1 assem-
blies. Overall, the intracellular uorescence intensity was
observed to be lower for each sample in HeLa cells compared to
RAWmacrophages. One of the reasons could be the diﬀerences
in the particle uptake mechanisms. For instance, non-specic
transcytosis49 as well as several endocytic pathways have been
reported to be involved in the uptake of QDs by RAW macro-
phages.56 Similarly, energy-dependent endocytosis has been
reported for QD uptake by HeLa cells.57 Although QD/VLP
assemblies are larger than QDs, they are still small enough to
be endocytosed by most endocytic mechanisms.58
Fig. 4 CLSM images of RAW 264.7 macrophages incubated with T¼ 1 particles, T¼ 3 particles, and QDs. Left: ﬂuorescence, middle: bright-ﬁeld,
right: merged images.
Fig. 5 Intracellular ﬂuorescence intensity levels measured using
CLSM. Each dot represents an individual cell and horizontal bars show
mean and standard deviation of the measurements. Unpaired t test
results: n.s., non-signiﬁcant (P > 0.05); ** and ***, signiﬁcant (P < 0.05).






























































































In vitro studies presented in our work provide a rst proof of
principle to use QD/VLP assemblies for in vitro imaging. More
detailed investigations are necessary to reveal the exact mech-
anisms, via which QD/VLP assemblies are taken up by diﬀerent
cell types that are relevant to potential in vivo applications.
Conclusions
A simple route for the formation of CCMV-based VLP/QD nano
hybrid particles with tuneable sizes as a function of pH and
ionic strength was shown. At low pH and high ionic strength
(pH 5.0, 1.0 M NaCl) capsid proteins assembled around the
carboxylic acid functionalized QDs to form particles of 27 nm
similar to T ¼ 3 native capsid symmetry via CP–CP attractions.
At high pH and low ionic strength (pH 7.5, 0.3 M NaCl), CP–QD
electrostatic attractions governed the formation of smaller
particles of 18 nm similar to T ¼ 1 icosahedral symmetry. Cell
viability assays implemented on RAW 264.7 macrophages
revealed no signs of toxicity during the incubation period at QD
concentrations exceeding the potentially toxic levels. The rst
proof of principle to use QD/VLP assemblies for in vitro imaging
was shown on HeLa cells. The reported encapsulation routes
can be adapted to encapsulation of other inorganic nano-
particles to obtain functional nano hybrid materials with
tuneable sizes and diﬀerent functions. This improve their
stability, reduce their cytotoxicity and the protein capsid can be
controllably functionalized, which are particularly promising
for in vitro and in vivo applications.
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Fig. 6 CLSM images of HeLa cells incubated with T ¼ 1 particles, T ¼ 3 particles, and QDs. Left: ﬂuorescence, middle: bright-ﬁeld, right: merged
images. Scale bar: 20 mm.
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